These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 34071939)

  • 41. Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis.
    Fernández Montes A; López López C; Argilés Martínez G; Páez López D; López Muñoz AM; García Paredes B; Gutiérrez Abad D; Castañón López C; Jiménez Fonseca P; Gallego Plazas J; López Doldán MC; Martínez de Castro E; Sánchez Cánovas M; Tobeña Puyal M; Llorente Ayala B; Juez Martel I; López Flores M; Carmona-Bayonas A
    Oncologist; 2019 Aug; 24(8):e687-e695. PubMed ID: 31147489
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
    Kim G; Cockrum P; Surinach A; Wang S; Wainberg Z
    Curr Med Res Opin; 2022 Aug; 38(8):1295-1303. PubMed ID: 35354375
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study.
    Guimbaud R; Louvet C; Ries P; Ychou M; Maillard E; André T; Gornet JM; Aparicio T; Nguyen S; Azzedine A; Etienne PL; Boucher E; Rebischung C; Hammel P; Rougier P; Bedenne L; Bouché O
    J Clin Oncol; 2014 Nov; 32(31):3520-6. PubMed ID: 25287828
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen.
    Sendur MA; Ozdemir N; Özatlı T; Yazıcı O; Aksoy S; Ekinci AS; Yazılıtaş D; Günaydın Y; Oksuzoglu B; Benekli M; Zengin N
    Med Oncol; 2014 Sep; 31(9):153. PubMed ID: 25099765
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.
    Ohtani H; Arimoto Y; Nishio K; Kanamiya Y; Oba H; Adachi K; Shintani M; Nakamura R; Yui S
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1769-74. PubMed ID: 18931586
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
    Berger MD; Stintzing S; Heinemann V; Yang D; Cao S; Sunakawa Y; Ning Y; Matsusaka S; Okazaki S; Miyamoto Y; Suenaga M; Schirripa M; Soni S; Zhang W; Falcone A; Loupakis F; Lenz HJ
    Ann Oncol; 2017 Nov; 28(11):2780-2785. PubMed ID: 29045529
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors.
    Wang D; Braiteh F; Lee JJ; Denlinger CS; Shepard DR; Chaudhary A; Lin Y; Gao L; Asakiewicz C; Nasroulah F; LoRusso P
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):727-33. PubMed ID: 27507037
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.
    Del Rio M; Molina F; Bascoul-Mollevi C; Copois V; Bibeau F; Chalbos P; Bareil C; Kramar A; Salvetat N; Fraslon C; Conseiller E; Granci V; Leblanc B; Pau B; Martineau P; Ychou M
    J Clin Oncol; 2007 Mar; 25(7):773-80. PubMed ID: 17327601
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Retrospective comparison of two different schedules of irinotecan, 5-fluorouracil and folinic acid in previously untreated patients with advanced colorectal carcinoma: a single institution experience.
    Gluzman A; Rubinov K; Mermershtain W; Man S; Ariad S; Lavrenkov K
    J Chemother; 2007 Dec; 19(6):739-43. PubMed ID: 18230559
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer.
    Masuishi T; Nagaoka S; Jin L; Yoshizawa K
    Drugs Real World Outcomes; 2023 Sep; 10(3):405-413. PubMed ID: 37103777
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
    Kashiwa M; Matsushita R
    Clin Ther; 2020 Jul; 42(7):1361-1375. PubMed ID: 32616433
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial.
    Sadahiro S; Suzuki T; Okada K; Saito G; Miyakita H; Ogimi T; Chan LF; Kamei Y
    Oncology; 2020; 98(9):637-642. PubMed ID: 32474564
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
    Pentheroudakis G; Mavroeidis L; Papadopoulou K; Koliou GA; Bamia C; Chatzopoulos K; Samantas E; Mauri D; Efstratiou I; Pectasides D; Makatsoris T; Bafaloukos D; Papakostas P; Papatsibas G; Bombolaki I; Chrisafi S; Kourea HP; Petraki K; Kafiri G; Fountzilas G; Kotoula V
    Clin Colorectal Cancer; 2019 Dec; 18(4):e370-e384. PubMed ID: 31402291
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer.
    Kim J; Kim H; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim ST
    J Cancer; 2021; 12(2):460-466. PubMed ID: 33391442
    [No Abstract]   [Full Text] [Related]  

  • 55. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
    Bertagnolli MM; Niedzwiecki D; Compton CC; Hahn HP; Hall M; Damas B; Jewell SD; Mayer RJ; Goldberg RM; Saltz LB; Warren RS; Redston M
    J Clin Oncol; 2009 Apr; 27(11):1814-21. PubMed ID: 19273709
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping.
    Lu CY; Yeh YS; Huang CW; Ma CJ; Yu FJ; Wang JY
    Onco Targets Ther; 2014; 7():2143-6. PubMed ID: 25473295
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.
    Ychou M; Hohenberger W; Thezenas S; Navarro M; Maurel J; Bokemeyer C; Shacham-Shmueli E; Rivera F; Kwok-Keung Choi C; Santoro A
    Ann Oncol; 2009 Dec; 20(12):1964-70. PubMed ID: 19567451
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    Van Cutsem E; Köhne CH; Hitre E; Zaluski J; Chang Chien CR; Makhson A; D'Haens G; Pintér T; Lim R; Bodoky G; Roh JK; Folprecht G; Ruff P; Stroh C; Tejpar S; Schlichting M; Nippgen J; Rougier P
    N Engl J Med; 2009 Apr; 360(14):1408-17. PubMed ID: 19339720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FOLFIRI as second-line chemotherapy after failure of FOLFOX4 in advanced colorectal cancer: a Korean single-center experience.
    Kim JH; Park SJ; Park MI; Moon W; Kim SE; Ku KH; Song SE; Kim JH
    Korean J Gastroenterol; 2014 Jan; 63(1):18-24. PubMed ID: 24463284
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
    Teufel A; Steinmann S; Siebler J; Zanke C; Hohl H; Adami B; Schroeder M; Klein O; Höhler T; Galle PR; Heike M; Moehler M
    BMC Cancer; 2004 Jul; 4():38. PubMed ID: 15265233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.